CN104721186A - Application of pravastatin (PRAV) to preparation of medicine for promoting apoptosis of human lung adenocarcinoma A549 cells - Google Patents
Application of pravastatin (PRAV) to preparation of medicine for promoting apoptosis of human lung adenocarcinoma A549 cells Download PDFInfo
- Publication number
- CN104721186A CN104721186A CN201510136611.3A CN201510136611A CN104721186A CN 104721186 A CN104721186 A CN 104721186A CN 201510136611 A CN201510136611 A CN 201510136611A CN 104721186 A CN104721186 A CN 104721186A
- Authority
- CN
- China
- Prior art keywords
- apoptosis
- pravastatin
- medicine
- lung adenocarcinoma
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to application of pravastatin (PRAV) to preparation of a medicine for promoting the apoptosis of human lung adenocarcinoma A549 cells and mainly aims to solve the problem of insignificant effects of chemotherapy on lung adenocarcinoma. The invention is characterized by the application of pravastatin (PRAV) to preparation of a medicine for promoting the apoptosis of human lung adenocarcinoma A549 cells. PRAV can be used for effectively inhibiting the proliferation of lung cancer cells in vitro and inducing the apoptosis of human lung adenocarcinoma A549 cells, can be used for improving the sensitivity of chemotherapeutic medicines and can assist chemotherapeutic medicines in inhibiting tumors.
Description
Technical field:
The present invention relates to the purposes field of pravastatin for the preparation of medicine, especially a kind of pravastatin is for the preparation of the application for the treatment of apoptosis of human lung adenocarcinoma A 549 medicine.
Background technology:
Pulmonary carcinoma is one of major malignant tumor threatening human health, the annual new cases about 1,600,000 in the whole world.Along with the change of China's spectrum of disease, pulmonary carcinoma has become China's town and country mortality of malignant tumors first cause, accounts for 22.7% of whole mortality of malignant tumors.Modal is clinically nonsmall-cell lung cancer (non-small cell lung cancer, NLCSC), account for 80% of all pulmonary carcinoma, and adenocarcinoma of lung sickness rate constantly increases from last century Mo, replace lung squamous cancer at present, become modal histological type.Adenocarcinoma of lung, because its incubation period is longer, when making a definite diagnosis, patient many places are the late period of cancer, and in recent years along with the increase gradually of people's life stress, the sickness rate of advanced pulmonary adenocarcinoma presents the trend risen year by year, which results in the great attention of academia to it, therefore find medicine safely and effectively, to treat advanced pulmonary adenocarcinoma, there is great clinical meaning.In the forming process of malignant tumor, the expression of gene participating in apoptosis plays key player.The sudden change of apoptosis-related genes, disappearance or overexpression, can cause apoptosis obstacle or infinite multiplication relatively, thus lead oncogenic generations development and to chemotherapeutics generation drug resistance.Therefore, the how expression of Effective Regulation apoptosis-related genes or its product, promotes apoptosis of tumor cells, is improve the efficient key point of oncotherapy.Chemotherapy occupies consequence in Treatment for Non-small Cell Lung, but multidrug resistance and adverse effect comparatively generally affect its curative effect.
At present, the cause of disease of pulmonary carcinoma and pathogenesis are illustrated not yet completely in the world, but from angle, the propagation of cancerous cell and the abnormal to the growth of cell and playing an important role of tumor of apoptosis of oncocytology.The death of malignant cell and the equal defectiveness of apoptosis compared with normal cell, and Apoptosis inhibitor often causes growth of tumour cell out of control in tumor cell.Apoptosis is the basic biological phenomena of one of cell, has important biological significance and the Molecular Biology Mechanism of complexity, plays an important role in the forming process of malignant tumor.Apoptosis is the active death process of cell, and it is one of important mechanisms of tumorigenesis that apoptosis is escaped, and promotes that apoptosis is a kind of important mechanisms of antineoplastic.The same with cell proliferation, apoptosis is also the accurate process by gene regulation, mainly contains 2 approach: activate caspase-3 (Caspase-3) by the death receptor on cell membrane and cause apoptosis; Activate Caspase-9 by cytochrome C release in kytoplasm mitochondrial, and then activation Caspase-3 promotes apoptosis.BCL-2 family protein member participates in regulating apoptotic generation, is regulatory factor important in apoptotic process.These albumen are mainly distributed in the endomembrane system of cell, mitochondrial inner membrane and nuclear membrane distribute especially abundant.BCL-2 family gene is divided into 2 classes: a class promotes that apoptogene is as BAX, and a class presses down apoptogene as BAX-2.Therefore the destiny of cell depends on and the ratio of the homology that formed and heterodimer between mitochondrial inner membrane surface BCL-2 family anti-apoptotic and short apoptosis member.Although the induced factor of apoptosis is varied, all must by the apoptosis pathway regulating the expression of apoptogene (short apoptogene and apoptosis inhibit gene) to come active cell inside.Once this path is activated, the generation of apoptosis will be irreversible.
Summary of the invention:
The invention reside in and overcome Problems existing in background technology, and provide a kind of pravastatin for the preparation of the new opplication for the treatment of apoptosis of human lung adenocarcinoma A 549 medicine.Pravastatin effectively can suppress the in-vitro multiplication of lung carcinoma cell, and induction apoptosis of human lung adenocarcinoma A 549, can also strengthen the sensitivity of chemotherapeutics.
The present invention solves its problem and reaches by following technical scheme: a kind of pravastatin is for the preparation of the application for the treatment of apoptosis of human lung adenocarcinoma A 549 medicine.
Described pravastatin can also for the preparation of the application of adjuvant therapy of tumors medicine; The patient increased blood fat is more applicable, plays primary prevention and secondary prevention effect to coronary heart disease.
Described consumption is 20mg/d; The highest use can arrive 40mg/d; 1 time on the one, administering mode is oral, takes before liking to sleep most.
Statins is the competitive inhibitor of the rate-limiting enzyme HMG-CoA reductase of cholesterol biosynthesis, active by reducing HMG-CoA reductase, reduce synthesis and retardance methylol valeric acid (MVA) approach of intracellular cholesteryl, suppress kinds of tumor cells propagation, differentiation-inducing and apoptosis.
Pravastatin (PRAV) is the competitive inhibitor of 3-hydroxyl 3-methyl glutaryl coenzyme A (HMG-CoA) reductase, it suppresses the synthesis of cholesterol by the rate-limiting enzyme HMG-CoA reductase in reversible inhibition Biosynthesis of cholesterol process, reduces LDL level in blood.And PRAV is the one of Statins, the sensitivity of cancerous cell to chemotherapy can be strengthened, except effect for reducing fat, also have simultaneously and reverse Endothelial Dysfunction, immunity moderation function, effect such as pleiotropy such as minimizing ventricular arrhythmia and thrombosis etc.To tumor cell, there is Inhibit proliferaton, differentiation-inducing or apoptosis, suppression blood vessel occur, reduce the effects such as invasive ability.Statins all has remarkable inhibitory action to multiple cancerous cell such as carcinoma of prostate, cancer of pancreas, melanoma, bladder cancer and breast carcinoma, and it is little to normal impact cell, it is the more potential antitumor drug of one, affect very little, if some cancer patients increases with blood fat simultaneously, apply this medicine will effect better.
The present invention can have following beneficial effect compared with above-mentioned background technology: this pravastatin is for the preparation of the application for the treatment of apoptosis of human lung adenocarcinoma A 549 medicine, pravastatin effectively can suppress the in-vitro multiplication of lung carcinoma cell, and in time dependence and concentration dependent; PRAV can also strengthen the sensitivity of chemotherapeutics, also has adjunct antineoplastic effect.This medicine can tentatively be applied to clinical, adjuvant therapy of tumors, especially nonsmall-cell lung cancer, and the patient increased blood fat is more applicable.
Accompanying drawing illustrates:
Accompanying drawing 1 is the picture of Lung Adenocarcinoma A 549 Cell under optical microscope of the present invention.
Detailed description of the invention:
Below in conjunction with specific embodiment, the invention will be further described:
Embodiment 1
Purchaser's lung adenocarcinoma cells A549, carry out external cellar culture, the collecting cell when exponential phase, Methyl thiazoly tetrazolium assay (tetrzolium-based colorimetric assay, MTT) method is adopted to detect 0umol/L, 5umol/L, 10umol/L, 20umol/L, 40umol/L concentration group and (24h, 48h, 72h) time group PRAV impact on cell survival and growth.Application flow cytometer (flow cytometry, FCM) measures three time points, and the PRAV of variable concentrations is on the impact of A549 cell cycle distribution and apoptosis.Here is the optical microscope picture of Lung Adenocarcinoma A 549 Cell, sees Fig. 1.PRAV variable concentrations and action time on the apoptotic impact of A549 in table 1.
The suppression ratio (x ± s) of the lower A549 cell of table 1PRAV effect
Table 1 is visible, and the same time compares P < 0.05 with matched group; Same concentration compares P < 0.01 with 24h
Flow cytomery apoptosis rate result shows, PRAV has obvious intervention effect to apoptosis, percentage rate increases with PRAV concentration and increases, with matched group (non-dosing group) comparing difference, there is significance (P<0.05), and have obvious time dependence, action time is longer, affects larger.
From above-described embodiment, pravastatin effectively can suppress the in-vitro multiplication of lung carcinoma cell, and in time dependence and concentration dependent; Inducing its tune to die may be one of mechanism of pravastatin antitumaous effect.PRAV can also strengthen the sensitivity of chemotherapeutics in addition, also has adjunct antineoplastic effect.This medicine can tentatively be applied to clinical, adjuvant therapy of tumors, and the patient increased blood fat is more applicable.
Case 1: patient week so-and-so, man, 58 years old, Daqing, Heilongjiang Province, suffer from adenocarcinoma of lung, patient has hyperlipidemia simultaneously, likes edible animal meat and long-term alcohol, suffers from adenocarcinoma of lung and be admitted to hospital, symptom: Progressive symmetric erythrokeratodermia dyspnea, cough, the display of outpatient service perspective, bilateral pleural effusion, the chemotherapy regimen treatment of application pemetrexed+cisplatin, and intrathecal anticarcinogen, take pravastatin treatment hyperlipidemia simultaneously, after 2 months, hydrothorax disappears, and the symptoms such as cough alleviate, breast lesion reduces, and alleviation is left hospital, without recurrence.
Case 2: patient Lee so-and-so, female, 57 years old, Qiqihaer City of Heilongjiang Province, local Diagnosis of pulmonary adenocarcinoma, suffered from serious blood fat high simultaneously, is in and takes the general Liprevil of blood lipid-lowering medicine always.Symptom: Progressive symmetric erythrokeratodermia dyspnea, supraclavicular lymph nodes enlargement, and with spitting of blood, inappetence, continues after being admitted to hospital to take pravastatin treatment hyperlipidemia, the chemotherapy regimen treatment of application pemetrexed+cisplatin, through the treatment of 2 months, patients symptomatic obviously alleviated, and left hospital after 3 months.
Claims (4)
1. a pravastatin is for the preparation of the application for the treatment of apoptosis of human lung adenocarcinoma A 549 medicine.
2. pravastatin according to claim 1 is for the preparation of the application for the treatment of apoptosis of human lung adenocarcinoma A 549 medicine, it is characterized in that: described pravastatin can also for the preparation of the application of adjuvant therapy of tumors medicine.
3. pravastatin according to claim 1 is used for auxiliary treatment apoptosis of human lung adenocarcinoma A 549, it is characterized in that: the patient that described pravastatin increases blood fat is more applicable, plays primary prevention and secondary prevention effect to coronary heart disease.
4. the pravastatin according to claim 1 or 2 or 3 is for the preparation of the application for the treatment of apoptosis of human lung adenocarcinoma A 549 medicine, and it is characterized in that: consumption is 20mg/d, 1 time on the one, administering mode is oral.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510136611.3A CN104721186A (en) | 2015-03-26 | 2015-03-26 | Application of pravastatin (PRAV) to preparation of medicine for promoting apoptosis of human lung adenocarcinoma A549 cells |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510136611.3A CN104721186A (en) | 2015-03-26 | 2015-03-26 | Application of pravastatin (PRAV) to preparation of medicine for promoting apoptosis of human lung adenocarcinoma A549 cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104721186A true CN104721186A (en) | 2015-06-24 |
Family
ID=53445986
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510136611.3A Pending CN104721186A (en) | 2015-03-26 | 2015-03-26 | Application of pravastatin (PRAV) to preparation of medicine for promoting apoptosis of human lung adenocarcinoma A549 cells |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104721186A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005000208A2 (en) * | 2003-05-30 | 2005-01-06 | Combinatorx, Inc. | Combination therapy for the treatment of neoplasms |
| CN1980662A (en) * | 2004-07-01 | 2007-06-13 | 默克公司 | Mitotic kinesin inhibitors |
-
2015
- 2015-03-26 CN CN201510136611.3A patent/CN104721186A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005000208A2 (en) * | 2003-05-30 | 2005-01-06 | Combinatorx, Inc. | Combination therapy for the treatment of neoplasms |
| CN1980662A (en) * | 2004-07-01 | 2007-06-13 | 默克公司 | Mitotic kinesin inhibitors |
Non-Patent Citations (1)
| Title |
|---|
| YA-FAN YEH ETC.: "Enhancing Effect of Dietary Cholesterol and Inhibitory Effect of Pravastatin on Allergic Pulmonary Inflammation", 《JOURNAL OF BIOMEDICAL SCIENCE》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sodrul et al. | Role of ginsenosides in reactive oxygen species-mediated anticancer therapy | |
| Yen et al. | 4β-Hydroxywithanolide E from Physalis peruviana (golden berry) inhibits growth of human lung cancer cells through DNA damage, apoptosis and G 2/M arrest | |
| Luo et al. | EGCG inhibited bladder cancer T24 and 5637 cell proliferation and migration via PI3K/AKT pathway | |
| Long et al. | Mulberry anthocyanins improves thyroid cancer progression mainly by inducing apoptosis and autophagy cell death | |
| Ponizovskiy | Warburg effect mechanism as the target for theoretical substantiation of new possibility cancer disease treatment | |
| Lee et al. | Nutritional supplements and their effect on glucose control | |
| Chiang et al. | Amentoflavone induces apoptosis and reduces expression of anti-apoptotic and metastasis-associated proteins in bladder cancer | |
| Yue et al. | Andrographis paniculata elicits anti-invasion activities by suppressing TM4SF3 gene expression and by anoikis-sensitization in esophageal cancer cells | |
| Zhang et al. | Wogonoside induces autophagy-related apoptosis in human glioblastoma cells | |
| Noor et al. | A systematic review of molecular hydrogen therapy in cancer management | |
| Ranjbar Bushehri et al. | Anti-inflammatory activity of peiminine in acetic acid-induced ulcerative colitis model | |
| Liu et al. | The herb medicine formula “chong lou fu fang” increases the cytotoxicity of chemotherapeutic agents and down-regulates the expression of chemotherapeutic agent resistance-related genes in human gastric cancer cells in vitro | |
| CN104721186A (en) | Application of pravastatin (PRAV) to preparation of medicine for promoting apoptosis of human lung adenocarcinoma A549 cells | |
| Tian et al. | Use of compound Chinese medicine in the treatment of lung cancer | |
| Yao et al. | Grape seed proanthocyanidins induce apoptosis through the mitochondrial pathway in nasopharyngeal carcinoma CNE-2 cells | |
| CN110302211A (en) | Arsenic trioxide combines the application of ascorbic acid in the treatment of colon cancer | |
| Li et al. | Piceatannol inhibits proliferation and induces apoptosis of bladder cancer cells through regulation of the PTEN/AKT signal pathway | |
| Hongguang et al. | Clinical effect of the extract of TCM Fructus akebiae combined with ursodeoxycholic acid on nonalcoholic fatty liver disease. | |
| CN112618569A (en) | Medicine for treating urothelial cancer | |
| CN104055786B (en) | The application in preparation preventing and treating tumour medicine of medicagenic acid-3-O-β-D-pyranglucoside, medicagenic acid and salt thereof | |
| CN102846594A (en) | New application of isopentene-based flavonoids compound in drug | |
| Wang et al. | Anticancer effect and molecular mechanism of ginsenoside Rg3 in various cancer types | |
| CN105902561A (en) | Application of Gracilariopsis lemaneiformis polysaccharide as antitumor chemotherapy drug synergist and antitumor drug | |
| Ziccarelli | Nutrition therapy for severe viral infections (COVID-19): recommendations and considerations for integrative medical treatments | |
| Yue et al. | Baicalin: a prominent therapeutic agent against colorectal cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150624 |
|
| RJ01 | Rejection of invention patent application after publication |